Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Average PT from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been given a consensus rating of “Reduce” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $7.42.

BHC has been the topic of a number of research analyst reports. Jefferies Financial Group restated a “hold” rating and set a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada reduced their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th.

Bausch Health Companies Trading Down 3.6 %

NYSE BHC opened at $6.15 on Monday. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The stock has a 50-day moving average of $7.48 and a 200-day moving average of $7.47. The firm has a market cap of $2.22 billion, a PE ratio of -12.82, a price-to-earnings-growth ratio of 0.34 and a beta of 0.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mountain Hill Investment Partners Corp. purchased a new position in shares of Bausch Health Companies during the 4th quarter worth approximately $56,000. Bank of Nova Scotia purchased a new position in shares of Bausch Health Companies during the 4th quarter worth approximately $83,000. One68 Global Capital LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter worth approximately $90,000. Alpine Global Management LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter worth approximately $114,000. Finally, Tobam grew its stake in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after buying an additional 1,422 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.